AgingResearch.NewsJoin free

TransDerm

CompanyUnited States

TransDerm develops one asset, in phase 1 (TD201 in pachyonychia congenita). Mostly small molecule acting on autophagy, mTOR signalling and MTOR; based in the United States.

1
Asset
Furthest stage
Phase 1
1
Trial
0
Signals

Pipeline

1

  • TD201

    Topical formulation of sirolimus that selectively inhibits mTOR complex 1.

    Phase 1, Small molecule, Autophagy, mTOR signalling, pachyonychia congenita

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms4
  • Trials1
  • Similar companies6

Intelligence